Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The overall aim of the project is to investigate how artificial intelligence (AI) can be used to streamline and at the same time increase diagnostic safety in breast cancer screening with mammography. AI has been shown in a number of studies to have great potential for both increasing diagnostic certainty (e.g. reduced occurrence of interval cancers) and at the same time reducing the workload for doctors. However, much research remains to clinically validate these new tools and to increase the understanding of how they affect the work of doctors. The specific goal of the project is to investigate whether the implementation of AI in breast cancer screening in Östergötland, Sweden, can increase the sensitivity (the mammography examination's ability to find breast cancer) and the specificity (that is, the right case is selected for further investigation: a minimum of healthy women are recalled but so many breast cancer cases that are possible are selected for further investigation) and at the same time make screening more efficient through reduced workload. AI will be implemented in the clinical routine and performance metrics such as cancer detection rate etc will be closely monitored. The study do not assign specific interventions to the study participants.
The overall aim of the project is to study whether the use of artificial intelligence can improve breast cancer screening with mammography. AI will be implemented in the clinical routine and performance metrics such as cancer detection rate etc will be closely monitored. The study do not assign specific interventions to the study participants. The specific objective is to investigate whether the use of AI leads to increased diagnostic safety in mammography in Östergötland (measured as a reduced incidence of interval cancer) and at the same time leads to a reduced workload for the breast radiologists. Furthermore, the intention is to investigate how the use of AI affects the breast radiologists´ work in terms of reading time per examination and whether the radiologists' specificity and sensitivity are affected when they have access to the decision support based on AI during the review compared to if they do not have this support.
The hypotheses are that:
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Screened women in Region Östergötland, Sweden | All screened women in Region Östergötland, Sweden. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AI cancer detection system | Device | The AI system Transpara (Screenpoint Medical, The Netherlands) will be implemented for triaging two-image mammography examinations based on the probability of malignancy. Transpara assigns a score from 1 to 10 to each examination, indicating the risk of malignancy. A score between 1 and 7 indicates a low risk of cancer, 8-9 indicates an intermediate and 10 an elevated risk of cancer. Examinations with an AI score between 1 and 7 will be reviewed by only one radiologist, while examinations with an AI score > 7 will be double-reviewed as normal. |
| Measure | Description | Time Frame |
|---|---|---|
| Cancer Detection rate | Proportion of women diagnosed with breast cancer among those recalled after consensus | 4 Years |
| Positive predictive value of Transpara® scores | Proportion of breast cancers diagnosed among women with a given AI score | 4 Years |
Not provided
Not provided
Inclusion Criteria:
Women participating in the regular Breast Cancer Screening Program in Region Östergötland
Exclusion Criteria:
Women with breast implants or other foreign implants in the mammogram Women with symptoms or signs of suspected breast cancer
Not provided
Not provided
Women eligible for population-based mammography screening
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Håkan Gustafsson, Ph.D. | Region Östergötland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Region Östergötland | Linköping | Östergötland County | Sweden |
No individual participant data (IPD) will be shared.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001941 | Breast Diseases |
| D009369 | Neoplasms |
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
|
|